Treatment of latent tuberculosis infection a network meta-analysis

Annals of Internal Medicine

Volumn 161, Issue 6, 2014, Pages 419-428

  Stagg, Helen R ^a   Zenner, Dominik ^b   Harris, Ross J ^b   Muñoz, Laura ^c   Lipman, Marc C ^d   Abubakar, Ibrahim ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PLACEBO; RIFAMPICIN; DRUG DERIVATIVE; PYRAZINAMIDE; RIFAPENTINE; TUBERCULOSTATIC AGENT;

CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); EMBASE; HEALTH CARE POLICY; HUMAN; INFECTION PREVENTION; LANGUAGE; LATENT TUBERCULOSIS; LIVER TOXICITY; MEDLINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARD; TUBERCULOSIS; TUBERCULOSIS CONTROL; WEB OF SCIENCE; DRUG ADMINISTRATION; DRUG COMBINATION; META ANALYSIS; TOXIC HEPATITIS;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN;

EID: 84907197223     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-1019     Document Type: Review

References (83)

1. Centers for Disease Control and Prevention. Treatment of latent TB infection. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Accessed at www.cdc.gov/tb/publications/ltbi/treatment.htm on 5 November 2013.
2. Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 2010; 14:1374-81. [PMID: 20937175]
3. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013; 7: CD007545. [PMID: 23828580] doi:10.1002/14651858.CD007545.pub2
4. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365:2155-66. [PMID: 22150035] doi:10.1056/NEJMoa1104875
5. Ades AE. A chain of evidence with mixed comparisons: models for multiparameter synthesis and consistency of evidence. Stat Med. 2003; 22:2995-3016. [PMID: 12973783]
6. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002; 21:2313-24. [PMID: 12210616]
7. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. [PMID: 22008217] doi:10.1136/bmj.d5928
8. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med. 2012; 157:429-38. [PMID: 22945832]
9. National Cancer Institute. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Bethesda, MD: National Cancer Insitute; 2010. Accessed at http://evs.nci.nih.gov/ftp1/CTCAE/About.html on 14 August 2013.
10. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004; 23:3105-24. [PMID: 15449338]
11. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009; 28:1861-81. [PMID: 19399825] doi:10.1002/sim.3594
12. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med. 2003; 22:3687-709. [PMID: 14652869]
13. Brooks SP. MCMC convergence diagnosis via multivariate bounds on log-concave densities. Annals of Statistics. 1998; 26:398-433.
14. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol. 2002; 64:583-640. doi: 10.1111/1467-9868.00353
15. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Sheffield, United Kingdom: Univ of Sheffield; 2011. Accessed at www.cc-arcc.ca/common/pages/UserFile.aspx?fileId=282149 on 8 July 2014.
16. Trinquart L, Chatellier G, Ravaud P. Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Med Res Methodol. 2012; 12:150. [PMID: 23016799] doi:10.1186/1471-2288-12-150
17. Sanchez F, Balagué M, Hernandez P, López-Colomés JL, Garćia de Olalla P, Garćia Vidal J, Guerrero R. Treatment of latent tuberculosis infection in injecting drug users co-infected by HIV. Enf Emerg 2002; 4:62-5.
18. Sanchez F, Balagué M, Garćia de Olalla P, López Colomés JL, Martín V, Guerrero R, Marco A, Caylà JA. Treatment of latent mycobacterium tuberculosis infection in intravenous drug users co-infected with HIV. Journal of Infection Prevention. 2010; 11:12-8. doi: 10.1177/1757177409354732
19. Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011; 66:496-501. [PMID: 21460373] doi:10.1136/thx.2010.156752
20. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000; 283:1445-50. [PMID: 10732934]
21. Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ; Terry Beirn Community Programs for Clinical Research on AIDS. Hepatotoxicity of rifam-pin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis. 2004; 39:561-5. [PMID: 15356822]
22. Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, et al; Uganda-Case Western Reserve University Research Collaboration. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001; 15:2137-47. [PMID: 11684933]
23. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997; 337:801-8. [PMID: 9295239]
24. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998; 12:2447-57. [PMID: 9875583]
25. Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JDH, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 2001; 15:215-22. [PMID: 11216930]
26. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al; P1041 Study Team. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011; 365:21-31. [PMID: 21732834] doi:10.1056/NEJMoa1011214
27. Portilla J, Jordá P, Esteban J, Sánchez-Payá J, Merino E, Boix V; Grupo de Estudio Protocolo-INH. [Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens]. Enferm Infecc Microbiol Clin. 2003; 21:293-5. [PMID: 12809583]
28. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007; 45:715-22. [PMID: 17712755]
29. Bush OB Jr, Sugimoto M, Fujii Y, Brown FA Jr. Isoniazid prophylaxis in contacts of persons with known tuberculosis. Second report. Am Rev Respir Dis. 1965; 92:732-40. [PMID: 5321147]
30. del Castillo H, Bautista LD, Jacinto CP, Lorenzo CE, Lapuz S, Legaspi B. Chemoprophylaxis in the Philippines: a controlled pilot study among household contacts of tuberculosis cases. Bulletin of the Quezon Institute. 1965; 7:277-90.
31. Egsmose T, Ang'awa JO, Poti SJ. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ. 1965; 33:419-33. [PMID: 5321762]
32. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis. 1962; 85:490-510. [PMID: 13892318]
33. Geijo MP, Herranz CR, Vaño D, Garćia AJ, Garćia M, Dimas JF. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. Enferm Infecc Microbiol Clin. 2007; 25: 300-4. [PMID: 17504682]
34. Gupta DK, Kumar R, Nath N, Kothari AK. Chemoprophylaxis in high-risk children-analysis of 8 years' follow-up: preliminary report. Indian Journal of Tuberculosis. 1993; 40:125-7.
35. Martínez Alfaro E, Solera J, Serna E, Cuenca D, Castillejos ML, Espinosa A, et al. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]. Med Clin (Barc). 1998; 111:401-4. [PMID: 9834911]
36. Mount FW, Ferebee SH. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis. 1962; 85:821-7. [PMID: 14476668]
37. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006; 173:922-6. [PMID: 16474028]
38. Tortajada C, Martínez-Lacasa J, Sánchez F, Jiménez-Fuentes A, De Souza ML, Garćia JF, et al; Tuberculosis Prevention Working Group. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis. 2005; 9:276-81. [PMID: 15786890]
39. Veening GJ. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc. 1968; 41:169-71. [PMID: 4885378]
40. Magdorf K, Arizzi-Rusche AF, Geiter LJ, O'Brien RJ, Wahn U. [Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood-a pilot project]. Pneumologie. 1994; 48:761-4. [PMID: 7808991]
41. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007; 334:136. [PMID: 17085459]
42. Agarwal SK, Gupta S, Dash SC, Bhowmik D, Tiwari SC. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol. 2004; 36:425-31. [PMID: 15783119]
43. Fitzgerald DW, Severe P, Joseph P, Mellon LR, Noel E, Johnson WD Jr, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial [Letter]. J Acquir Immune Defic Syndr. 2001; 28:305-7. [PMID: 11694842]
44. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1997; 337:315-20. [PMID: 9233868]
45. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998; 351:786-92. [PMID: 9519950]
46. Hawken MP, Meme HK, Elliott LC, Chakaya JM, Morris JS, Githui WA, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS. 1997; 11:875-82. [PMID: 9189212]
47. John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JC. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation. 1994; 57:1683-4. [PMID: 8009608]
48. Martínez Alfaro EM, Cuadra F, Solera J, Maciá MA, Geijo P, Sánchez Martínez PA, et al. [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group]. Med Clin (Barc). 2000; 115:161-5. [PMID: 10996870]
49. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011; 365:11-20. [PMID: 21732833] doi:10.1056/NEJMoa1005136
50. Matteelli A, Olliaro P, Signorini L, Cadeo G, Scalzini A, Bonazzi L, et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isonia-zid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis. 1999; 3:1043-6. [PMID: 10587327]
51. Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuberc Lung Dis. 2007; 11:1114-20. [PMID: 17945069]
52. Naqvi R, Naqvi A, Akhtar S, Ahmed E, Noor H, Saeed T, et al. Use of isoniazid chemoprophylaxis in renal transplant recipients. Nephrol Dial Transplant. 2010; 25:634-7. [PMID: 19783599] doi:10.1093/ndt/gfp489
53. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993; 342:268-72. [PMID: 8101302]
54. Rivero A, López-Cortés L, Castillo R, Verdejo J, Garćia MA, Martínez-Marcos FJ, et al; Grupo Andaluz para el estudio de las Enfermedades Infeccio-sas (GAEI). [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. Enferm Infecc Microbiol Clin. 2007; 25:305-10. [PMID: 17504683]
55. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377:1588-98. [PMID: 21492926] doi:10.1016/S0140-6736(11)60204-3
56. Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012; 7:e47400. [PMID: 23251327] doi:10.1371/journal.pone.0047400
57. Vikrant S, Agarwal SK, Gupta S, Bhowmik D, Tiwari SC, Dash SC, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis. 2005; 7:99-108. [PMID: 16390397]
58. Xie QB, Wen FQ, Yin G. [Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009; 40:138-40. [PMID: 19292064]
59. Chan PC, Yang CH, Chang LY, Wang KF, Lu BY, Lu CY, et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis. 2012; 16:633-8. [PMID: 22410137] doi:10.5588/ijtld.11.0504
60. Cowie RL. Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial. Tuber Lung Dis. 1996; 77:239-43. [PMID: 8758107]
61. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992; 145:36-41. [PMID: 1731596]
62. Leung CC, Law WS, Chang KC, Tam CM, Yew WW, Chan CK, et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest. 2003; 124:2112-8. [PMID: 14665488]
63. Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ. 1966; 35:509-26. [PMID: 5335457]
64. Bailey WC, Weill H, DeRouen TA, Ziskind MM, Jackson HA. The effect of isoniazid on transaminase levels. Ann Intern Med. 1974; 81:200-2. [PMID: 4843577]
65. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967; 95: 935-43. [PMID: 6026165]
66. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982; 60:555-64. [PMID: 6754120]
67. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010: CD000171. [PMID: 20091503] doi:10.1002/14651858.CD000171.pub3
68. Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis. 2014; 14:91. [PMID: 24555539] doi:10.1186/1471-2334-14-91
69. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000: CD001363. [PMID: 10796642]
70. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004:CD000171. [PMID: 14973947]
71. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculous infection. MMWR. 2000; 49:1-54. Accessed at www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm on 14 June 2014.
72. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999; 3:847-50. [PMID: 10524579]
73. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011; 133:257-66. [PMID: 21441678]
74. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007:CD005159. [PMID: 17943842]
75. Centers for Disease Control and Prevention (CDC). Impact of a shortage of first-line antituberculosis medication on tuberculosis control-United States, 2012-2013. MMWR Morb Mortal Wkly Rep. 2013; 62:398-400. [PMID: 23698604]
76. Debre R, Perdrizet S, Lotte A, Naveau M, Lert F. Isoniazid chemoprophy-laxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969. Int J Epidemiol. 1973; 2:153-60. [PMID: 4204799]
77. Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII. Chest. 1978; 73:44-8. [PMID: 340155]
78. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis. 1963; 88:161-75. [PMID: 14045220]
79. Jiménez-Fuentes MA, de Souza-Galvao ML, Mila Auge C, Solsona Peiró J, Altet-Gómez MN. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population. Int J Tuberc Lung Dis. 2013; 17:326-32. [PMID: 23407221] doi:10.5588/ijtld.12.0510
80. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004; 170: 445-9. [PMID: 15172892]
81. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008; 149:689-97. [PMID: 19017587]
82. Sánchez-Arcilla I, Vílchez JM, Garćia de la Torre M, Fernandez X, Nogu-erado A. [Treatment of latent tuberculosis among homeless population. Comparison between two therapeutic approaches]. Med Clin (Barc). 2004; 122:57-9. [PMID: 14733856]
83. White MC, Tulsky JP, Lee JR, Chen L, Goldenson J, Spetz J, et al. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care. 2012; 18:131-42. [PMID: 22419641] doi:10.1177/1078345811435973